Direct antiviral agents for hepatitis C and drug interaction risk: A retrospective cohort study with real and simulated data on medication interaction, prevalence of comorbidities and comedications
Comorbidities and comedication are common in patients with hepatitis C, which could result in a risk of drug-drug interaction. The objective of this study was to evaluate the prevalence of comorbidities, comedication and drug-drug interactions involving direct-acting antivirals in this population. C...
Gespeichert in:
| Veröffentlicht in: | PloS one 2021-02, Vol.16 (2), p.e0245767 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 2 |
| container_start_page | e0245767 |
| container_title | PloS one |
| container_volume | 16 |
| creator | Boff da Costa, Raquel Boff Costa, Marisa Longo, Larisse Miotto, Daniela Elisa Hirata Dellavia, Gustavo Trucollo Michalczuk, Matheus Reis Álvares-da-Silva, Mario |
| description | Comorbidities and comedication are common in patients with hepatitis C, which could result in a risk of drug-drug interaction. The objective of this study was to evaluate the prevalence of comorbidities, comedication and drug-drug interactions involving direct-acting antivirals in this population.
Comorbidities and comedications were evaluated in a retrospective cohort of hepatitis C patients. Drug-drug interactions were estimated in real life and with simulated data on comedications following drug regimens: telaprevir; elbasvir/grazoprevir, ombitasvir/paritaprevir/r/ritonavir (2D regimen), and sofosbuvir/simeprevir, sofosbuvir/daclatasvir, sofosbuvir/ledipasvir; 2D/dasabuvir (3D regimen); glecaprevir/pibrentasvir and sofosbuvir/velpatasvir/voxilaprevir. The interactions were evaluated according to the University of Liverpool database. Statistical analysis was performed by SPSS® 18.0.
Data from 1433 patients with hepatitis C were evaluated. The mean patient age was 51.7 years (SD ± 10.7), and 50.6% were female. Direct-acting antivirals were prescribed for 345 (24.1%) patients, and a sustained virological response occurred in 264 (76.5%). The main comorbidities were systemic arterial hypertension [436 (30.4%)], diabetes mellitus [352 (24.6%)] and depression [130 (9.1%)]. The mean number of comorbidities was 1.52 (median [IQR] of 1.00 [1.00-2.00]). The mean number of comedications was 3.16 (median [IQR] of 3.00 [1.00-5.00]). A total of 12916 drug-drug interactions were found, of which 1.859 (14.4%) were high risk, with a mean of 1.29 ± 3.13 per patient. The 3D regimen, as well as glecaprevir/pibrentasvir and sofosbuvir/velpatasvir/voxilaprevir, presented the highest drug-drug interaction indexes.
Comorbidities and comedications are common in patients with hepatitis C, as are drug-drug interactions. Even when second generation drugs are used, the occurrence of drug-drug interactions still presents a significant risk. |
| doi_str_mv | 10.1371/journal.pone.0245767 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_proquest_journals_2489016043</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A651631734</galeid><doaj_id>oai_doaj_org_article_a5dcf362650a43a0a9f1cdfd523fbb50</doaj_id><sourcerecordid>A651631734</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-3fdbf1bbca5a1d4043426e5d910261e1fed39e483a5f7884e503d74d6badd9ff3</originalsourceid><addsrcrecordid>eNqNk1uLEzEUgAdR3LX6D0QDgiDYmkxmMh0fhFJvhYUFb6_hTC5t6nRSk0x1f6D_y9PLlhYUZB4yJN_5kpyck2WPGR0xXrFXS9-HDtrR2ndmRPOirER1J7tkNc-HIqf87sn_RfYgxiWlJR8LcT-74LysqrLml9nvty4YlQh0yW1cgJbA3HQpEusDWZg1JJdcJFMENNGhnxPXJRNAJec7Elz8_ppMSDAp-LhGkdsYovzCh0Ri6vUN-enSAte3YjREt-pbSAZdkICgYmW0U7CznZhfknUwG2hNpwzxFpUrHxqn8TAm7kw4c4yMD7N7FtpoHh3GQfb1_bsv04_Dq-sPs-nkaqhEnacht7qxrGkUlMB0QQte5MKUumY0F8wwazSvTTHmUNpqPC5MSbmuCi0a0Lq2lg-yp3vvuvVRHl4gyrwY15QJ9CEx2xPaw1Kug1tBuJEenNxN-DCXEJJTrZFQamW5yEVJoeBAobZMaavLnNumwa0H2ZvDbn2Dl1X4LvhAZ9Lzlc4t5NxvJJ6d4s1Q8OwgCP5Hb2L6x5EP1BzzLV1nPcrUykUlJ6JkgrOKF0iN_kLhp83KKaxB63D-LODFWQAyyfxKc-hjlLPPn_6fvf52zj4_YRdYWWkRfdvvCuEcLPagwtqMwdhj5hiV2xa6zYbctpA8tBCGPTnN-jHotmf4H6k8HPw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2489016043</pqid></control><display><type>article</type><title>Direct antiviral agents for hepatitis C and drug interaction risk: A retrospective cohort study with real and simulated data on medication interaction, prevalence of comorbidities and comedications</title><source>MEDLINE</source><source>Full-Text Journals in Chemistry (Open access)</source><source>Directory of Open Access Journals</source><source>Public Library of Science</source><source>PubMed Central</source><source>EZB Electronic Journals Library</source><creator>Boff da Costa, Raquel ; Boff Costa, Marisa ; Longo, Larisse ; Miotto, Daniela Elisa ; Hirata Dellavia, Gustavo ; Trucollo Michalczuk, Matheus ; Reis Álvares-da-Silva, Mario</creator><contributor>Negida, Ahmed</contributor><creatorcontrib>Boff da Costa, Raquel ; Boff Costa, Marisa ; Longo, Larisse ; Miotto, Daniela Elisa ; Hirata Dellavia, Gustavo ; Trucollo Michalczuk, Matheus ; Reis Álvares-da-Silva, Mario ; Negida, Ahmed</creatorcontrib><description>Comorbidities and comedication are common in patients with hepatitis C, which could result in a risk of drug-drug interaction. The objective of this study was to evaluate the prevalence of comorbidities, comedication and drug-drug interactions involving direct-acting antivirals in this population.
Comorbidities and comedications were evaluated in a retrospective cohort of hepatitis C patients. Drug-drug interactions were estimated in real life and with simulated data on comedications following drug regimens: telaprevir; elbasvir/grazoprevir, ombitasvir/paritaprevir/r/ritonavir (2D regimen), and sofosbuvir/simeprevir, sofosbuvir/daclatasvir, sofosbuvir/ledipasvir; 2D/dasabuvir (3D regimen); glecaprevir/pibrentasvir and sofosbuvir/velpatasvir/voxilaprevir. The interactions were evaluated according to the University of Liverpool database. Statistical analysis was performed by SPSS® 18.0.
Data from 1433 patients with hepatitis C were evaluated. The mean patient age was 51.7 years (SD ± 10.7), and 50.6% were female. Direct-acting antivirals were prescribed for 345 (24.1%) patients, and a sustained virological response occurred in 264 (76.5%). The main comorbidities were systemic arterial hypertension [436 (30.4%)], diabetes mellitus [352 (24.6%)] and depression [130 (9.1%)]. The mean number of comorbidities was 1.52 (median [IQR] of 1.00 [1.00-2.00]). The mean number of comedications was 3.16 (median [IQR] of 3.00 [1.00-5.00]). A total of 12916 drug-drug interactions were found, of which 1.859 (14.4%) were high risk, with a mean of 1.29 ± 3.13 per patient. The 3D regimen, as well as glecaprevir/pibrentasvir and sofosbuvir/velpatasvir/voxilaprevir, presented the highest drug-drug interaction indexes.
Comorbidities and comedications are common in patients with hepatitis C, as are drug-drug interactions. Even when second generation drugs are used, the occurrence of drug-drug interactions still presents a significant risk.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0245767</identifier><identifier>PMID: 33577593</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adverse events ; Age ; Age Distribution ; Alanine ; Alanine transaminase ; Albumins ; Antiviral agents ; Antiviral Agents - pharmacology ; Antiviral Agents - therapeutic use ; Antiviral drugs ; Aspartate aminotransferase ; Bilirubin ; Biology and life sciences ; Biopsy ; Blood glucose ; Blood transfusion ; Cholesterol ; Cirrhosis ; Clinical aspects ; Cohort analysis ; Comorbidity ; Complications and side effects ; Cost analysis ; Creatinine ; Data analysis ; Diabetes ; Drug addiction ; Drug interaction ; Drug Interactions ; Editing ; Experimental research ; Female ; Fibrosis ; Gastroenterology ; Genotypes ; Health risks ; Hepatitis ; Hepatitis C ; Hepatitis C - drug therapy ; Hepatology ; HIV ; Hospitals ; Human immunodeficiency virus ; Humans ; Laboratories ; Light effects ; Liver cirrhosis ; Male ; Medical records ; Medicine ; Medicine and Health Sciences ; Methodology ; Middle Aged ; Platelets ; Prevalence ; Prothrombin ; Public health ; Retrospective Studies ; Reviews ; Risk analysis ; Risk Factors ; Ritonavir ; Sexually transmitted diseases ; STD ; Testing ; Transfusion ; Transplantation ; Triglycerides ; Visualization</subject><ispartof>PloS one, 2021-02, Vol.16 (2), p.e0245767</ispartof><rights>COPYRIGHT 2021 Public Library of Science</rights><rights>2021 Boff da Costa et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 Boff da Costa et al 2021 Boff da Costa et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-3fdbf1bbca5a1d4043426e5d910261e1fed39e483a5f7884e503d74d6badd9ff3</citedby><cites>FETCH-LOGICAL-c692t-3fdbf1bbca5a1d4043426e5d910261e1fed39e483a5f7884e503d74d6badd9ff3</cites><orcidid>0000-0002-1665-8208 ; 0000-0002-4453-7227</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7880426/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7880426/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,2928,23866,27924,27925,53791,53793,79472,79473</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33577593$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Negida, Ahmed</contributor><creatorcontrib>Boff da Costa, Raquel</creatorcontrib><creatorcontrib>Boff Costa, Marisa</creatorcontrib><creatorcontrib>Longo, Larisse</creatorcontrib><creatorcontrib>Miotto, Daniela Elisa</creatorcontrib><creatorcontrib>Hirata Dellavia, Gustavo</creatorcontrib><creatorcontrib>Trucollo Michalczuk, Matheus</creatorcontrib><creatorcontrib>Reis Álvares-da-Silva, Mario</creatorcontrib><title>Direct antiviral agents for hepatitis C and drug interaction risk: A retrospective cohort study with real and simulated data on medication interaction, prevalence of comorbidities and comedications</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Comorbidities and comedication are common in patients with hepatitis C, which could result in a risk of drug-drug interaction. The objective of this study was to evaluate the prevalence of comorbidities, comedication and drug-drug interactions involving direct-acting antivirals in this population.
Comorbidities and comedications were evaluated in a retrospective cohort of hepatitis C patients. Drug-drug interactions were estimated in real life and with simulated data on comedications following drug regimens: telaprevir; elbasvir/grazoprevir, ombitasvir/paritaprevir/r/ritonavir (2D regimen), and sofosbuvir/simeprevir, sofosbuvir/daclatasvir, sofosbuvir/ledipasvir; 2D/dasabuvir (3D regimen); glecaprevir/pibrentasvir and sofosbuvir/velpatasvir/voxilaprevir. The interactions were evaluated according to the University of Liverpool database. Statistical analysis was performed by SPSS® 18.0.
Data from 1433 patients with hepatitis C were evaluated. The mean patient age was 51.7 years (SD ± 10.7), and 50.6% were female. Direct-acting antivirals were prescribed for 345 (24.1%) patients, and a sustained virological response occurred in 264 (76.5%). The main comorbidities were systemic arterial hypertension [436 (30.4%)], diabetes mellitus [352 (24.6%)] and depression [130 (9.1%)]. The mean number of comorbidities was 1.52 (median [IQR] of 1.00 [1.00-2.00]). The mean number of comedications was 3.16 (median [IQR] of 3.00 [1.00-5.00]). A total of 12916 drug-drug interactions were found, of which 1.859 (14.4%) were high risk, with a mean of 1.29 ± 3.13 per patient. The 3D regimen, as well as glecaprevir/pibrentasvir and sofosbuvir/velpatasvir/voxilaprevir, presented the highest drug-drug interaction indexes.
Comorbidities and comedications are common in patients with hepatitis C, as are drug-drug interactions. Even when second generation drugs are used, the occurrence of drug-drug interactions still presents a significant risk.</description><subject>Adverse events</subject><subject>Age</subject><subject>Age Distribution</subject><subject>Alanine</subject><subject>Alanine transaminase</subject><subject>Albumins</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - pharmacology</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Antiviral drugs</subject><subject>Aspartate aminotransferase</subject><subject>Bilirubin</subject><subject>Biology and life sciences</subject><subject>Biopsy</subject><subject>Blood glucose</subject><subject>Blood transfusion</subject><subject>Cholesterol</subject><subject>Cirrhosis</subject><subject>Clinical aspects</subject><subject>Cohort analysis</subject><subject>Comorbidity</subject><subject>Complications and side effects</subject><subject>Cost analysis</subject><subject>Creatinine</subject><subject>Data analysis</subject><subject>Diabetes</subject><subject>Drug addiction</subject><subject>Drug interaction</subject><subject>Drug Interactions</subject><subject>Editing</subject><subject>Experimental research</subject><subject>Female</subject><subject>Fibrosis</subject><subject>Gastroenterology</subject><subject>Genotypes</subject><subject>Health risks</subject><subject>Hepatitis</subject><subject>Hepatitis C</subject><subject>Hepatitis C - drug therapy</subject><subject>Hepatology</subject><subject>HIV</subject><subject>Hospitals</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Laboratories</subject><subject>Light effects</subject><subject>Liver cirrhosis</subject><subject>Male</subject><subject>Medical records</subject><subject>Medicine</subject><subject>Medicine and Health Sciences</subject><subject>Methodology</subject><subject>Middle Aged</subject><subject>Platelets</subject><subject>Prevalence</subject><subject>Prothrombin</subject><subject>Public health</subject><subject>Retrospective Studies</subject><subject>Reviews</subject><subject>Risk analysis</subject><subject>Risk Factors</subject><subject>Ritonavir</subject><subject>Sexually transmitted diseases</subject><subject>STD</subject><subject>Testing</subject><subject>Transfusion</subject><subject>Transplantation</subject><subject>Triglycerides</subject><subject>Visualization</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk1uLEzEUgAdR3LX6D0QDgiDYmkxmMh0fhFJvhYUFb6_hTC5t6nRSk0x1f6D_y9PLlhYUZB4yJN_5kpyck2WPGR0xXrFXS9-HDtrR2ndmRPOirER1J7tkNc-HIqf87sn_RfYgxiWlJR8LcT-74LysqrLml9nvty4YlQh0yW1cgJbA3HQpEusDWZg1JJdcJFMENNGhnxPXJRNAJec7Elz8_ppMSDAp-LhGkdsYovzCh0Ri6vUN-enSAte3YjREt-pbSAZdkICgYmW0U7CznZhfknUwG2hNpwzxFpUrHxqn8TAm7kw4c4yMD7N7FtpoHh3GQfb1_bsv04_Dq-sPs-nkaqhEnacht7qxrGkUlMB0QQte5MKUumY0F8wwazSvTTHmUNpqPC5MSbmuCi0a0Lq2lg-yp3vvuvVRHl4gyrwY15QJ9CEx2xPaw1Kug1tBuJEenNxN-DCXEJJTrZFQamW5yEVJoeBAobZMaavLnNumwa0H2ZvDbn2Dl1X4LvhAZ9Lzlc4t5NxvJJ6d4s1Q8OwgCP5Hb2L6x5EP1BzzLV1nPcrUykUlJ6JkgrOKF0iN_kLhp83KKaxB63D-LODFWQAyyfxKc-hjlLPPn_6fvf52zj4_YRdYWWkRfdvvCuEcLPagwtqMwdhj5hiV2xa6zYbctpA8tBCGPTnN-jHotmf4H6k8HPw</recordid><startdate>20210212</startdate><enddate>20210212</enddate><creator>Boff da Costa, Raquel</creator><creator>Boff Costa, Marisa</creator><creator>Longo, Larisse</creator><creator>Miotto, Daniela Elisa</creator><creator>Hirata Dellavia, Gustavo</creator><creator>Trucollo Michalczuk, Matheus</creator><creator>Reis Álvares-da-Silva, Mario</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-1665-8208</orcidid><orcidid>https://orcid.org/0000-0002-4453-7227</orcidid></search><sort><creationdate>20210212</creationdate><title>Direct antiviral agents for hepatitis C and drug interaction risk: A retrospective cohort study with real and simulated data on medication interaction, prevalence of comorbidities and comedications</title><author>Boff da Costa, Raquel ; Boff Costa, Marisa ; Longo, Larisse ; Miotto, Daniela Elisa ; Hirata Dellavia, Gustavo ; Trucollo Michalczuk, Matheus ; Reis Álvares-da-Silva, Mario</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-3fdbf1bbca5a1d4043426e5d910261e1fed39e483a5f7884e503d74d6badd9ff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adverse events</topic><topic>Age</topic><topic>Age Distribution</topic><topic>Alanine</topic><topic>Alanine transaminase</topic><topic>Albumins</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - pharmacology</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Antiviral drugs</topic><topic>Aspartate aminotransferase</topic><topic>Bilirubin</topic><topic>Biology and life sciences</topic><topic>Biopsy</topic><topic>Blood glucose</topic><topic>Blood transfusion</topic><topic>Cholesterol</topic><topic>Cirrhosis</topic><topic>Clinical aspects</topic><topic>Cohort analysis</topic><topic>Comorbidity</topic><topic>Complications and side effects</topic><topic>Cost analysis</topic><topic>Creatinine</topic><topic>Data analysis</topic><topic>Diabetes</topic><topic>Drug addiction</topic><topic>Drug interaction</topic><topic>Drug Interactions</topic><topic>Editing</topic><topic>Experimental research</topic><topic>Female</topic><topic>Fibrosis</topic><topic>Gastroenterology</topic><topic>Genotypes</topic><topic>Health risks</topic><topic>Hepatitis</topic><topic>Hepatitis C</topic><topic>Hepatitis C - drug therapy</topic><topic>Hepatology</topic><topic>HIV</topic><topic>Hospitals</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Laboratories</topic><topic>Light effects</topic><topic>Liver cirrhosis</topic><topic>Male</topic><topic>Medical records</topic><topic>Medicine</topic><topic>Medicine and Health Sciences</topic><topic>Methodology</topic><topic>Middle Aged</topic><topic>Platelets</topic><topic>Prevalence</topic><topic>Prothrombin</topic><topic>Public health</topic><topic>Retrospective Studies</topic><topic>Reviews</topic><topic>Risk analysis</topic><topic>Risk Factors</topic><topic>Ritonavir</topic><topic>Sexually transmitted diseases</topic><topic>STD</topic><topic>Testing</topic><topic>Transfusion</topic><topic>Transplantation</topic><topic>Triglycerides</topic><topic>Visualization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Boff da Costa, Raquel</creatorcontrib><creatorcontrib>Boff Costa, Marisa</creatorcontrib><creatorcontrib>Longo, Larisse</creatorcontrib><creatorcontrib>Miotto, Daniela Elisa</creatorcontrib><creatorcontrib>Hirata Dellavia, Gustavo</creatorcontrib><creatorcontrib>Trucollo Michalczuk, Matheus</creatorcontrib><creatorcontrib>Reis Álvares-da-Silva, Mario</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Opposing Viewpoints in Context (Gale)</collection><collection>Science (Gale in Context)</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health Medical collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>https://resources.nclive.org/materials</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>Biological Sciences</collection><collection>Agriculture Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>ProQuest Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Boff da Costa, Raquel</au><au>Boff Costa, Marisa</au><au>Longo, Larisse</au><au>Miotto, Daniela Elisa</au><au>Hirata Dellavia, Gustavo</au><au>Trucollo Michalczuk, Matheus</au><au>Reis Álvares-da-Silva, Mario</au><au>Negida, Ahmed</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Direct antiviral agents for hepatitis C and drug interaction risk: A retrospective cohort study with real and simulated data on medication interaction, prevalence of comorbidities and comedications</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2021-02-12</date><risdate>2021</risdate><volume>16</volume><issue>2</issue><spage>e0245767</spage><pages>e0245767-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Comorbidities and comedication are common in patients with hepatitis C, which could result in a risk of drug-drug interaction. The objective of this study was to evaluate the prevalence of comorbidities, comedication and drug-drug interactions involving direct-acting antivirals in this population.
Comorbidities and comedications were evaluated in a retrospective cohort of hepatitis C patients. Drug-drug interactions were estimated in real life and with simulated data on comedications following drug regimens: telaprevir; elbasvir/grazoprevir, ombitasvir/paritaprevir/r/ritonavir (2D regimen), and sofosbuvir/simeprevir, sofosbuvir/daclatasvir, sofosbuvir/ledipasvir; 2D/dasabuvir (3D regimen); glecaprevir/pibrentasvir and sofosbuvir/velpatasvir/voxilaprevir. The interactions were evaluated according to the University of Liverpool database. Statistical analysis was performed by SPSS® 18.0.
Data from 1433 patients with hepatitis C were evaluated. The mean patient age was 51.7 years (SD ± 10.7), and 50.6% were female. Direct-acting antivirals were prescribed for 345 (24.1%) patients, and a sustained virological response occurred in 264 (76.5%). The main comorbidities were systemic arterial hypertension [436 (30.4%)], diabetes mellitus [352 (24.6%)] and depression [130 (9.1%)]. The mean number of comorbidities was 1.52 (median [IQR] of 1.00 [1.00-2.00]). The mean number of comedications was 3.16 (median [IQR] of 3.00 [1.00-5.00]). A total of 12916 drug-drug interactions were found, of which 1.859 (14.4%) were high risk, with a mean of 1.29 ± 3.13 per patient. The 3D regimen, as well as glecaprevir/pibrentasvir and sofosbuvir/velpatasvir/voxilaprevir, presented the highest drug-drug interaction indexes.
Comorbidities and comedications are common in patients with hepatitis C, as are drug-drug interactions. Even when second generation drugs are used, the occurrence of drug-drug interactions still presents a significant risk.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>33577593</pmid><doi>10.1371/journal.pone.0245767</doi><tpages>e0245767</tpages><orcidid>https://orcid.org/0000-0002-1665-8208</orcidid><orcidid>https://orcid.org/0000-0002-4453-7227</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2021-02, Vol.16 (2), p.e0245767 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_proquest_journals_2489016043 |
| source | MEDLINE; Full-Text Journals in Chemistry (Open access); Directory of Open Access Journals; Public Library of Science; PubMed Central; EZB Electronic Journals Library |
| subjects | Adverse events Age Age Distribution Alanine Alanine transaminase Albumins Antiviral agents Antiviral Agents - pharmacology Antiviral Agents - therapeutic use Antiviral drugs Aspartate aminotransferase Bilirubin Biology and life sciences Biopsy Blood glucose Blood transfusion Cholesterol Cirrhosis Clinical aspects Cohort analysis Comorbidity Complications and side effects Cost analysis Creatinine Data analysis Diabetes Drug addiction Drug interaction Drug Interactions Editing Experimental research Female Fibrosis Gastroenterology Genotypes Health risks Hepatitis Hepatitis C Hepatitis C - drug therapy Hepatology HIV Hospitals Human immunodeficiency virus Humans Laboratories Light effects Liver cirrhosis Male Medical records Medicine Medicine and Health Sciences Methodology Middle Aged Platelets Prevalence Prothrombin Public health Retrospective Studies Reviews Risk analysis Risk Factors Ritonavir Sexually transmitted diseases STD Testing Transfusion Transplantation Triglycerides Visualization |
| title | Direct antiviral agents for hepatitis C and drug interaction risk: A retrospective cohort study with real and simulated data on medication interaction, prevalence of comorbidities and comedications |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T16%3A59%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Direct%20antiviral%20agents%20for%20hepatitis%20C%20and%20drug%20interaction%20risk:%20A%20retrospective%20cohort%20study%20with%20real%20and%20simulated%20data%20on%20medication%20interaction,%20prevalence%20of%20comorbidities%20and%20comedications&rft.jtitle=PloS%20one&rft.au=Boff%20da%20Costa,%20Raquel&rft.date=2021-02-12&rft.volume=16&rft.issue=2&rft.spage=e0245767&rft.pages=e0245767-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0245767&rft_dat=%3Cgale_plos_%3EA651631734%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2489016043&rft_id=info:pmid/33577593&rft_galeid=A651631734&rft_doaj_id=oai_doaj_org_article_a5dcf362650a43a0a9f1cdfd523fbb50&rfr_iscdi=true |